News Releases
Previous All pages Next 1 2 3 Page 4 5 6 7 8 9
March 17, 2008  Sernova Corp. Grants Stock Options
December 10, 2007  Successful Completion of Preclinical Sertolin Study: Regulatory Guidance Sought for Clinical Approval
September 24, 2007  FDA Consultant to Help Guide Sernova Through Regulatory Approval Process
September 10, 2007  Sertoli Cells Successfully Engineered to Secrete Insulin and are Effective in Preclinical Models of Diabetes
July 30, 2007  Sernova Files Worldwide Patent Application for Innovative Component of Diabetes
May 09, 2007  Sernova Raises $2.4 Million to Advance Sertolin to Clinical Trails
May 03, 2007  Sernova Directors and Management Established for 2007/2008 -- Dr. George Adams Named Chair; Justin Leushner Becomes CEO
April 16, 2007  Journal of Clinical Immunology: Sertoli Cells Could Replace Immunosuppressive Drugs in Humans
April 02, 2007  Sernova Corp. Information To Be Available Through S&P Market Access Program
February 05, 2007  Pre-Clinical Milestones for Sertolin Cell Replacement Technology: Insulin-Producing Cells Survive and Function without Anti-Rejection Drugs
Previous All pages Next 1 2 3 Page 4 5 6 7 8 9